Technical Analysis for IMVT - Immunovant, Inc.

Grade Last Price % Change Price Change
F 30.27 -0.85% -0.26
IMVT closed down 0.85 percent on Monday, March 18, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
New Downtrend Bearish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish -0.85%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 16 hours ago
Rose Above 200 DMA about 16 hours ago
200 DMA Resistance about 19 hours ago
60 Minute Opening Range Breakout about 19 hours ago
Fell Below Previous Day's Low about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Eye Autoimmune Disease Antibodies Monoclonal Antibodies Monoclonal Antibody Anemia Thyroid Eye Diseases Treatment Of Autoimmune Disease Myasthenia Gravis Transfusion Medicine Myasthenia Thyroid Eye Disease Acquired Hemolytic Anemia Treatment Of Myasthenia Gravis

Is IMVT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 45.58
52 Week Low 14.05
Average Volume 1,239,277
200-Day Moving Average 30.70
50-Day Moving Average 37.02
20-Day Moving Average 34.22
10-Day Moving Average 31.79
Average True Range 1.65
RSI (14) 26.47
ADX 25.22
+DI 10.67
-DI 28.65
Chandelier Exit (Long, 3 ATRs) 34.59
Chandelier Exit (Short, 3 ATRs) 34.67
Upper Bollinger Bands 39.61
Lower Bollinger Band 28.84
Percent B (%b) 0.13
BandWidth 31.46
MACD Line -1.85
MACD Signal Line -1.50
MACD Histogram -0.3436
Fundamentals Value
Market Cap 4.38 Billion
Num Shares 145 Million
EPS -1.96
Price-to-Earnings (P/E) Ratio -15.44
Price-to-Sales 0.00
Price-to-Book 20.38
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.50
Resistance 3 (R3) 31.54 31.18 31.30
Resistance 2 (R2) 31.18 30.86 31.16 31.23
Resistance 1 (R1) 30.72 30.67 30.54 30.68 31.16
Pivot Point 30.36 30.36 30.27 30.34 30.36
Support 1 (S1) 29.90 30.04 29.72 29.86 29.38
Support 2 (S2) 29.54 29.85 29.52 29.31
Support 3 (S3) 29.08 29.54 29.25
Support 4 (S4) 29.04